maritide glp-1 What to know about MariTide, Amgen's experimental drug Once Monthly Weight Loss Drug

Short-chain fatty acids, particularly butyrate and propionate, have been shown to activate receptors on enteroendocrine L-cells, triggering GLP-1 release

27 This proposal would classify obesity as a disease, providing a pathway around the federal law that blocks Medicare coverage of drugs used for weight loss

With regard to adverse effects, gastrointestinal intoleranceespecially nausea and vomitingrepresents the class-defining limitation

Given the extraordinary demand and exorbitant cost for these medications, particularly as people are using them for weight loss, I thought it would be helpful to talk about the role of compounding pharmacies